Furthermore, immunohistochemistry data from 132 melanoma patient tumor specimens (primary, n = 72; metastatic, n = 63) demonstrate that in the progression from primary to metastatic melanoma, IGFBP-4 expression decreases while integrin avb3 expression increases (data not shown). This evidence concerns the gene IGFBP4 and metastatic melanoma.